Addex (ADXN) - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים

Addex Therapeutics (ADXN) develops soft modulators for the treatment of dystonia and Parkinson's disease. This quarterly earnings per share chart demonstrates asset volatility, where the current metric is 18.50. The financial standing of the Swiss biotech is complicated by a lack of operating cash flow due to R&D expenditures. Future growth relies on cost optimization and the development of strategic neurobiological alliances.

Addex Therapeutics (ADXN) is scaling the development of allosteric modulators through B2B partnerships to expand its footprint in the neuropharmaceuticals segment. Net income per share dynamics measure the efficiency of cash generation to cover liabilities, where steady growth confirms fundamental business resilience, while sharp spikes without a base signal risks, as clearly illustrated by the current quarterly EPS trend on the GURU.Markets platform.